TOKYO -- With the U.S. regulators formally approving Alzheimer's disease treatment lecanemab, Japanese pharmaceutical company Eisai and American partner Biogen now turn to the challenge of taking the treatment mainstream.
Pharmaceuticals
Eisai's Alzheimer's drug takes step toward widespread use
Limited testing capacity could prove challenge in Japan
Lecanemab, branded as Leqembi, is expected to slow the progress of Alzheimer's disease by about seven months. (Photo courtesy of Eisai)
Read Next
%2520%E3%81%AE%E3%82%B3%E3%83%94%E3%83%BC.jpg?width=178&fit=cover&gravity=faces&dpr=2&quality=medium&source=nar-cms&format=auto&height=100)
.jpg?width=178&fit=cover&gravity=faces&dpr=2&quality=medium&source=nar-cms&format=auto&height=100)
Latest on Pharmaceuticals
